Education
About Us
Working with TipRanks
Follow Us
Spruce Biosciences, Inc. (SPRB)
:SPRB
SPRB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.11 - $0.87
Previous CloseN/A
Volume285.87K
Average Volume (3M)1.69M
Market Cap
$5.47M
Enterprise Value-$37.21M
Total Cash (Recent Filing)$81.15M
Total Debt (Recent Filing)$4.15M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
May 07, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding42,231,285
10 Day Avg. Volume4,518,442
30 Day Avg. Volume1,692,952
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.96
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap-6.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.58
Enterprise Value/Ebitda0.95
Forecast
1Y Price Target
$0.50Price Target Upside284.62% Upside
Rating ConsensusHold
Number of Analyst Covering3
---
Spruce Biosciences News
PremiumCompany Announcements
Spruce Biosciences Acquires TA-ERT for Rare Disease Focus
PremiumCompany Announcements
Spruce Biosciences Delays Annual Report Filing
PremiumCompany Announcements
Spruce Biosciences Appoints Interim Chief Medical Officer
---
Bulls Say, Bears Say
Bulls Say
Financial StabilitySpruce Biosciences ended 3Q24 with $60.1M in cash and cash equivalents, which is expected to be sufficient to fund operations at least into 2026.
Partnership OpportunitiesSPRB entered a low-risk partnership with HMNC Brain Health to run a Phase 2 proof-of-concept trial of tildacerfont in major depressive disorder.
Regulatory ApprovalAlignment has been reached with the FDA on a surrogate endpoint for Accelerated Approval, with a Biologics License Application targeted.
Bears Say
Cash BurnThe company's cash burn is expected to increase materially as it plans to build a commercial and medical affairs organization and initiate a pivotal study prior to approval.
Clinical Trial FailuresSpruce Biosciences disclosed disappointing data from recent studies with tildacerfont and has been evaluating strategic opportunities.
Funding ConcernsConcerns exist regarding Spruce Biosciences' ability to fund these programs without further shareholder dilution.
---
Ownership Overview
13.61% Insiders
2.67% Mutual Funds
<0.01% Other Institutional Investors
81.69% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SPRB FAQ
What was Spruce Biosciences, Inc.’s price range in the past 12 months?
Spruce Biosciences, Inc. lowest stock price was $0.11 and its highest was $0.87 in the past 12 months.
What is Spruce Biosciences, Inc.’s market cap?
Spruce Biosciences, Inc.’s market cap is $5.47M.
When is Spruce Biosciences, Inc.’s upcoming earnings report date?
Spruce Biosciences, Inc.’s upcoming earnings report date is May 07, 2025 which is in 12 days.
How were Spruce Biosciences, Inc.’s earnings last quarter?
Currently, no data Available
Is Spruce Biosciences, Inc. overvalued?
According to Wall Street analysts Spruce Biosciences, Inc.’s price is currently Undervalued.
Does Spruce Biosciences, Inc. pay dividends?
Spruce Biosciences, Inc. does not currently pay dividends.
What is Spruce Biosciences, Inc.’s EPS estimate?
Spruce Biosciences, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Spruce Biosciences, Inc. have?
Spruce Biosciences, Inc. has 42,231,285 shares outstanding.
What happened to Spruce Biosciences, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Spruce Biosciences, Inc.?
Among the largest hedge funds holding Spruce Biosciences, Inc.’s share is Aisling Capital Management LP. It holds Spruce Biosciences, Inc.’s shares valued at 0.
---
Company Description
Spruce Biosciences, Inc.
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
---
SPRB Stock 12 Month Forecast
Average Price Target
$0.50
▲(284.62% Upside)
Technical Analysis
---